These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

686 related articles for article (PubMed ID: 16953209)

  • 1. Autologous transplantation in elderly patients with multiple myeloma: are we asking the right questions?
    Klepin HD; Hurd DD
    Bone Marrow Transplant; 2006 Nov; 38(9):585-92. PubMed ID: 16953209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modern treatment options for elderly patients with multiple myeloma.
    Görner M; Späth-Schwalbe E;
    Onkologie; 2008 Jun; 31(6):335-42. PubMed ID: 18547977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Intensive treatment of multiple myeloma].
    Harousseau JL
    Bull Acad Natl Med; 2003; 187(2):405-13; discussion 413-5. PubMed ID: 14556449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IgD multiple myeloma--a clinical profile and outcome with chemotherapy and autologous stem cell transplantation.
    Wechalekar A; Amato D; Chen C; Keith Stewart A; Reece D
    Ann Hematol; 2005 Feb; 84(2):115-7. PubMed ID: 15503021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous stem cell transplantation beyond 60 years of age.
    Jantunen E
    Bone Marrow Transplant; 2006 Dec; 38(11):715-20. PubMed ID: 17041609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant.
    Cheema PK; Zadeh S; Kukreti V; Reece D; Chen C; Trudel S; Mikhael J
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):686-93. PubMed ID: 19450753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
    Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
    Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose treatment with autologous stem cell transplantation in multiple myeloma: past, present, and future.
    Björkstrand B; Gahrton G
    Semin Hematol; 2007 Oct; 44(4):227-33. PubMed ID: 17961721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent trends in the management of newly diagnosed multiple myeloma.
    Reece DE
    Curr Opin Hematol; 2009 Jul; 16(4):306-12. PubMed ID: 19491669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of stem cell transplantation.
    Harousseau JL
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):1157-74, x. PubMed ID: 17996593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frontline treatment in elderly patients with multiple myeloma.
    Facon T; San Miguel J; Mateos MV; Hulin C
    Semin Hematol; 2009 Apr; 46(2):133-42. PubMed ID: 19389497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis.
    Kumar SK; Dingli D; Lacy MQ; Dispenzieri A; Hayman SR; Buadi FK; Rajkumar SV; Litzow MR; Gertz MA
    Am J Hematol; 2008 Aug; 83(8):614-7. PubMed ID: 18429054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival.
    Lahuerta JJ; Mateos MV; Martínez-López J; Rosiñol L; Sureda A; de la Rubia J; García-Laraña J; Martínez-Martínez R; Hernández-García MT; Carrera D; Besalduch J; de Arriba F; Ribera JM; Escoda L; Hernández-Ruiz B; García-Frade J; Rivas-González C; Alegre A; Bladé J; San Miguel JF
    J Clin Oncol; 2008 Dec; 26(35):5775-82. PubMed ID: 19001321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health-related quality of life in multiple myeloma survivors treated with high dose chemotherapy followed by autologous peripheral blood progenitor cell transplantation: a retrospective analysis.
    Slovacek L; Slovackova B; Pavlik V; Hrstka Z; Macingova Z; Jebavy L; Horacek JM
    Neoplasma; 2008; 55(4):350-5. PubMed ID: 18505348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years.
    Mehta J; Singhal S
    Bone Marrow Transplant; 2007 Dec; 40(12):1101-14. PubMed ID: 17680020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of autologous stem cell transplantation in the management of multiple myeloma.
    Fermand JP; Brechignac S
    Pathol Biol (Paris); 1999 Feb; 47(2):199-202. PubMed ID: 10192889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003.
    Kristinsson SY; Landgren O; Dickman PW; Derolf AR; Björkholm M
    J Clin Oncol; 2007 May; 25(15):1993-9. PubMed ID: 17420512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma.
    Cavo M; Di Raimondo F; Zamagni E; Patriarca F; Tacchetti P; Casulli AF; Volpe S; Perrone G; Ledda A; Ceccolini M; Califano C; Bigazzi C; Offidani M; Stefani P; Ballerini F; Fiacchini M; de Vivo A; Brioli A; Tosi P; Baccarani M
    J Clin Oncol; 2009 Oct; 27(30):5001-7. PubMed ID: 19720903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.